News

PRESS RELEASES

Read the latest updates and announcements from ITF Therapeutics.

ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT^™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy

ITF Therapeutics LLC anuncia la disponibilidad comercial de DUVYZAT^™ (givinostat) en los EE. UU. para el tratamiento de pacientes con distrofia muscular de Duchenne

Italfarmaco Receives FDA Approval for Duvyzat^™ (givinostat) in Duchenne Muscular Dystrophy

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology

Publications

Learn more about our research in rare diseases.

Muscular Dystrophy Association Clinical & Scientific Conference 2024

Givinostat study in DMD: supportive results

Givinostat effects on DMD pathogenesis

For the Media

USA

Media inquiries: Brian Connor | +1 212 253 8881 | bconnor@berrypr.com
Other inquiries: Patient Advocacy and Communications Lead USA | c.allen@itftherapeutics.com

Global

Media inquiries: Charlotte Spitz or Jacob Verghese | +49 (0)151 7441 6179 | italfarmaco@trophic.eu
Other inquiries: Patient Advocacy and Communications Lead | s.parker@italfarmacogroup.com